Announcements Trials

Browse Landscape

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 1 Glioblastoma 1 Epilepsy 1

Interventions

Temozolomide 69 Radiotherapy 30 Bevacizumab 24 Carboplatin 13 pembrolizumab 12 Radiation 11 Carmustine 8 Irinotecan 7 temsirolimus 6 Surgical Procedures, Operative 6 Radiosurgery 6 Erlotinib Hydrochloride 6 atezolizumab 5 Vorinostat 5 Sirolimus 5 Radiotherapy, Intensity-Modulated 5 Nivolumab 5 Lomustine 5 Everolimus 5 fludarabine 4 Radiotherapy, Conformal 4 Magnetic Resonance Spectroscopy 4 Cyclophosphamide 4 Aminolevulinic Acid 4 tipifarnib 3 Sorafenib 3 Paclitaxel 3 IL13-PE38 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Gemcitabine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Glioblastoma × Sulfasalazine × Clear all

NCT05664464 2024-05-10

GLUGLIO

University of Zurich

Phase 1/2 Recruiting

Epilepsy, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡